Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 22 | 2024 | 2586 | 1.110 |
Why?
|
| Anti-HIV Agents | 5 | 2024 | 486 | 0.460 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2024 | 497 | 0.410 |
Why?
|
| Ambulatory Care Facilities | 2 | 2017 | 68 | 0.390 |
Why?
|
| Case Management | 1 | 2011 | 24 | 0.350 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2017 | 57 | 0.340 |
Why?
|
| Drug Monitoring | 1 | 2011 | 69 | 0.330 |
Why?
|
| Anti-Retroviral Agents | 2 | 2019 | 160 | 0.330 |
Why?
|
| Homosexuality, Male | 5 | 2019 | 486 | 0.330 |
Why?
|
| Sexual Partners | 8 | 2024 | 326 | 0.320 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2005 | 229 | 0.310 |
Why?
|
| Contact Tracing | 1 | 2007 | 25 | 0.270 |
Why?
|
| Hepatitis C | 2 | 2023 | 139 | 0.270 |
Why?
|
| Drug Resistance, Viral | 2 | 2005 | 67 | 0.260 |
Why?
|
| Community-Institutional Relations | 2 | 2017 | 219 | 0.260 |
Why?
|
| Medication Adherence | 2 | 2019 | 182 | 0.250 |
Why?
|
| Los Angeles | 8 | 2022 | 394 | 0.230 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2020 | 174 | 0.230 |
Why?
|
| HIV-1 | 4 | 2017 | 755 | 0.220 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2024 | 989 | 0.220 |
Why?
|
| Didanosine | 1 | 2003 | 3 | 0.210 |
Why?
|
| Nevirapine | 1 | 2003 | 8 | 0.210 |
Why?
|
| Oxazines | 1 | 2003 | 32 | 0.200 |
Why?
|
| HIV | 1 | 2004 | 100 | 0.200 |
Why?
|
| Hepatitis C, Chronic | 1 | 2023 | 44 | 0.200 |
Why?
|
| Social Support | 4 | 2024 | 445 | 0.200 |
Why?
|
| Urban Population | 1 | 2024 | 374 | 0.180 |
Why?
|
| Continuity of Patient Care | 1 | 2022 | 120 | 0.170 |
Why?
|
| Sexual Behavior | 4 | 2024 | 638 | 0.170 |
Why?
|
| Humans | 24 | 2024 | 43102 | 0.160 |
Why?
|
| Communication Barriers | 1 | 2020 | 60 | 0.160 |
Why?
|
| Adult | 15 | 2024 | 13872 | 0.150 |
Why?
|
| Risk-Taking | 7 | 2024 | 457 | 0.150 |
Why?
|
| Male | 17 | 2020 | 23409 | 0.150 |
Why?
|
| Condoms | 2 | 2019 | 150 | 0.150 |
Why?
|
| Mass Screening | 2 | 2014 | 541 | 0.150 |
Why?
|
| Hepacivirus | 2 | 2023 | 74 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 223 | 0.140 |
Why?
|
| Patient Compliance | 3 | 2017 | 233 | 0.140 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2017 | 12 | 0.140 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2017 | 129 | 0.130 |
Why?
|
| Central Nervous System Stimulants | 1 | 2019 | 180 | 0.130 |
Why?
|
| United States | 7 | 2013 | 5205 | 0.120 |
Why?
|
| Female | 14 | 2024 | 24698 | 0.120 |
Why?
|
| Young Adult | 6 | 2024 | 5080 | 0.120 |
Why?
|
| Adolescent | 6 | 2017 | 6081 | 0.120 |
Why?
|
| Medical History Taking | 1 | 2014 | 38 | 0.100 |
Why?
|
| Viral Load | 3 | 2022 | 348 | 0.090 |
Why?
|
| Truth Disclosure | 1 | 2011 | 26 | 0.090 |
Why?
|
| Stereotyping | 1 | 2011 | 45 | 0.090 |
Why?
|
| Health Personnel | 1 | 2014 | 277 | 0.090 |
Why?
|
| Middle Aged | 9 | 2024 | 12222 | 0.080 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 11 | 0.080 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 15 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 231 | 0.080 |
Why?
|
| Antigen Presentation | 1 | 2010 | 58 | 0.080 |
Why?
|
| Risk Factors | 4 | 2013 | 3994 | 0.080 |
Why?
|
| Stress, Psychological | 3 | 2013 | 661 | 0.080 |
Why?
|
| Sexuality | 1 | 2010 | 56 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2024 | 760 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2007 | 142 | 0.060 |
Why?
|
| Qualitative Research | 2 | 2024 | 574 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2007 | 148 | 0.060 |
Why?
|
| Depression | 1 | 2013 | 863 | 0.060 |
Why?
|
| Chicago | 1 | 2005 | 31 | 0.060 |
Why?
|
| Congresses as Topic | 1 | 2005 | 50 | 0.060 |
Why?
|
| Cultural Characteristics | 1 | 2005 | 128 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2007 | 863 | 0.050 |
Why?
|
| Professional-Patient Relations | 1 | 2004 | 60 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2010 | 1759 | 0.050 |
Why?
|
| Proprotein Convertases | 1 | 2023 | 8 | 0.050 |
Why?
|
| Cyclopropanes | 1 | 2003 | 46 | 0.050 |
Why?
|
| Alkynes | 1 | 2003 | 52 | 0.050 |
Why?
|
| Benzoxazines | 1 | 2003 | 47 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 153 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2023 | 73 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2003 | 201 | 0.050 |
Why?
|
| Logistic Models | 3 | 2013 | 1009 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2023 | 1600 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2024 | 138 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2003 | 321 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2023 | 195 | 0.040 |
Why?
|
| California | 2 | 2013 | 548 | 0.040 |
Why?
|
| AIDS Serodiagnosis | 1 | 2020 | 25 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 1234 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2003 | 1604 | 0.040 |
Why?
|
| Adenine | 1 | 2019 | 46 | 0.040 |
Why?
|
| Cross-Sectional Studies | 3 | 2013 | 3156 | 0.040 |
Why?
|
| Ritonavir | 1 | 2017 | 15 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 758 | 0.030 |
Why?
|
| Unsafe Sex | 1 | 2019 | 162 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2017 | 64 | 0.030 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2017 | 82 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2003 | 2544 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2017 | 178 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1063 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 205 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2014 | 102 | 0.020 |
Why?
|
| Program Development | 1 | 2014 | 240 | 0.020 |
Why?
|
| Morbidity | 1 | 2013 | 97 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2013 | 152 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 282 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 355 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 5 | 0.020 |
Why?
|
| HIV Antigens | 1 | 2010 | 5 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 7 | 0.020 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 7 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 197 | 0.020 |
Why?
|
| Amino Acids | 1 | 2010 | 148 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2010 | 171 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 416 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 352 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 184 | 0.020 |
Why?
|
| Bisexuality | 1 | 2011 | 211 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 423 | 0.020 |
Why?
|
| Disease Progression | 1 | 2010 | 667 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 876 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 863 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 638 | 0.010 |
Why?
|
| Heterosexuality | 1 | 2002 | 97 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 259 | 0.010 |
Why?
|
| Aged | 1 | 2014 | 8214 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2002 | 1285 | 0.010 |
Why?
|